Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX as Applicable in Patients with Idiopathic Overactive Bladder with Urinary Incontinence.

Next Previous
Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX as Applicable in Patients with Idiopathic Overactive Bladder with Urinary Incontinence.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBARK
  • Sponsors Allergan

Most Recent Events

  • 01 Nov 2023 Results of pooled post hoc analysis (n=1504 from studies NCT00910845, NCT00910520, NCT01767519, NCT01945489) assessing the effects of age, gender, and postvoid residual volume on catheterization rates after treatment with OnabotulinumtoxinA for Overactive Bladder published in the European Urology Open Science
  • 17 Oct 2021 Results of a pooled gender-focused analysis assessing long-term safety effects of onabotulinumtoxin A from following clinical studies: NCT00910845, NCT00910520, NCT01767519, NCT01945489 and NCT00915525 presented at the 51st Annual Meeting of the International Continence Society
  • 17 Oct 2021 Results (n=1564) of pooled analysis from two pivotal trials (NCT00910845 and NCT00910520) and two post-marketing studies (NCT01767519 and NCT01945489) assessing the efficacy and safety of onabotulinumtoxin A in a sufficient number of male patients with OAB and UI, presented at the 51st Annual Meeting of the International Continence Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top